Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer

Editors: Aman U. Buzdar and Steven E. Come

Summary Consensus Statement

Aman U. Buzdar, Steven E. Come, Angela Brodie, Paul E. Goss, Matthew Ellis, Stephen R. D. Johnston, James N. Ingle, Adrian V. Lee, Victor G. Vogel, Carol Hart

Estrogen Receptor: Current Understanding of Its Activation and Modulation
C. Kent Osborne, Rachel Schiff, Suzanne A.W. Fuqua, and Jiang Shou

Aromatase Inhibition and Inactivation
Angela Brodie and Brian Long

Prospects for Combining Hormonal and Nonhormonal Growth Factor Inhibition
Alan E. Wakeling, Robert I. Nicholson, and Julia M. W. Gee

The Role of Tamoxifen and Aromatase Inhibitors/Inactivators in Postmenopausal Patients
Kathleen I. Pritchard

Are Differences in the Available Aromatase Inhibitors and Inactivators Significant?
Paige E. Johnson and Aman Buzdar

Preliminary Experience with Pure Antiestrogens
Anthony Howell

Endocrine Manipulation in Advanced Breast Cancer: Recent Advances with SERM Therapies
Stephen R. D. Johnston

Neoadjuvant Endocrine Therapy for Breast Cancer: Medical Perspectives
Matthew J. Ellis

Current Status of Adjuvant Endocrine Therapy for Breast Cancer
James N. Ingle

Preliminary Data from Ongoing Adjuvant Aromatase Inhibitor Trials
Paul E. Goss

Future Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors
Anthony Howell

Future Directions Panel Discussion

Follow-Up of the Breast Cancer Prevention Trial and the Future of Breast Cancer Prevention Efforts
Victor G. Vogel

Benign Breast Disease and Breast Cancer Risk: Potential Role for Antiestrogens
Stuart J. Schnitt

The Potential for Aromatase Inhibition in Breast Cancer Prevention
Per E. Lønning, Lars Erik Kragh, Bjørn Erikstein, Anne Hagen, Terje Risberg, Ellen Slichting, Jürgen Geisler

Cross-Talk among Estrogen Receptor, Epidermal Growth Factor, and Insulin-like Growth Factor Signaling in Breast Cancer
Adrian V. Lee, Xiaojiang Cui, and Steffi Oesterreich

Inhibition of erbB Receptor (HER) Tyrosine Kinases as a Strategy to Abrogate Antiestrogen Resistance in Human Breast Cancer
Hirokazu Kurokawa and Carlos L. Arteaga

Author Index

CME Assessment Test and Evaluation Form
Cancer Research

7 (12 Supplement)

Cancer Res 2001;7:4392s-4401s.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/7/12_Supplement.citation

- **E-mail alerts**
  Sign up to receive free email-alerts related to this article or journal.

- **Reprints and Subscriptions**
  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

- **Permissions**
  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.